All News
Liver Management in Rheumatoid Arthritis - RNL2021 Highlight
While rheumatoid arthritis (RA) is not known to affect the liver directly, underlying liver disease and treatment-related effects on the liver can often become an obstacle in the management of many RA patients. In his Sunday presentation at RNL2021, Dr.
Read Article
Want to ask a question for the RheumNow Podcast? Record your question in 1 minute or less and we may feature it on an upcoming episode.
https://t.co/hOWU67uY1Y https://t.co/ooph09KuL9
Links:
Dr. John Cush RheumNow ( View Tweet)
News Feature: Rituximab vs. JAK inhibitors in Rheumatoid Lung Disease
https://t.co/2P0tdxvZD2 https://t.co/7gfE1CPSEx
Links:
Dr. John Cush RheumNow ( View Tweet)
Thanks to everyone who attended RheumNow Live 2021 in person and virtually! WE hope you enjoyed and learned from it. #RNL2021
Dr. John Cush RheumNow ( View Tweet)
Early RA pts given steroids (GC) do Not have short or long term benefits from GCs. 180 ERA pts given compared to 294 who did not. 5 yr F/U showed no differences in DAS28-CRP, HAQ or pain between groups. Steroids were used more in seronegative RA. https://t.co/CDUKDgsLRa
Links:
Dr. John Cush RheumNow ( View Tweet)
Using both glucocorticoids & PPI leads to additive risk of osteoporotic fractures - UK database studiedd 12351 RA pts - 1411 w/ OP Fx. Concomitant GCs + PPIs assoc w/ 1.6-fold risk of OP Fx (adj HR: 1.60) vs nonuse; more than 1.2-fold risk w/ either alone https://t.co/vvA6P5LEgs
Links:
Dr. John Cush RheumNow ( View Tweet)
We just started our last faculty panel on RA with audience Q&A.
#RNL2021 https://t.co/o1s2asdLcS
Dr. John Cush RheumNow ( View Tweet)
Mavrilimumab (anti-GM-CSF) metanalysis shows gret benefit in #RA - 1145 pts, 3 trials shows significant 12 week responses by: 1) DAS28-CRP remission (RR = 3.31); 2) ACR20 (RR = 2.38); 3) ACR50 (RR = 2.93) & 4) ACR70 (RR = 4.9). Where is it? https://t.co/9L5PFEB1DI
Links:
Dr. John Cush RheumNow ( View Tweet)
Spondyloarthritis faculty panel with audience Q&A #RNL2021 https://t.co/iSosAtHLCZ
Dr. John Cush RheumNow ( View Tweet)
Follow the hashtag #RNL2021 for all RheumNow Live coverage today!
Dr. John Cush RheumNow ( View Tweet)
Dr. Artie Kavanaugh leading the spondyloarthritis pod focusing on enthesitis and dactylitis management. #RNL2021 https://t.co/NCUwabTXVd
Dr. John Cush RheumNow ( View Tweet)
Join me at the @RheumNow SpA session happening now! #rheumatology #spondyloarthritis #ankylosing https://t.co/CTLq0xWQys
Nigil Haroon MD, PhD 💎🦜🌎🩺🔬 NigilHaroon ( View Tweet)
Leading the Rheumatoid Arthritis pod with discussions on pneumonia and RA and interstitial lung disease in RA. #RNL2021 https://t.co/psxMTHsOva
Dr. John Cush RheumNow ( View Tweet)
New podcast available! Dr. Jack Cush rants on the journal reports, news and FDA actions featured this past week on RheumNow.
https://t.co/rPnLp2NfRq https://t.co/TSTP2tWxXy
Links:
Dr. John Cush RheumNow ( View Tweet)
Our in-person participants engaging with the psoriatic panel #RNL2021 https://t.co/N0Cdos3Rhb
Dr. John Cush RheumNow ( View Tweet)
News Feature: Potent Topical Corticosteroids and the Risk of Osteoporotic Fractures
https://t.co/KazNPRXKNx https://t.co/pykBdbexzF
Links:
Dr. John Cush RheumNow ( View Tweet)
@RheumNow #RNL2021 Dr. Buttgereit on steroids in RA:
2.5 mg/d of prednisone increase total steroid amount in the body by 100% - great therapeutic effect but comes w/plethora of side effects.
Q: how do you feel out long term low dose steroids for RA?
Olga Petryna DrPetryna ( View Tweet)
Follow the hashtag #RNL2021 for all RheumNow Live coverage today and tomorrow!
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live has started! #RNL2021 https://t.co/CrNqnnKqUy
Dr. John Cush RheumNow ( View Tweet)
Metanalysis reveals significant heterogeneity in defining Refractory Disease in RA and polyarticular JIA. Should include: 1) Resistance to multiple drugs w/ different MOAs (≥2bDMARDs) and 2) Persistent symptoms and disease activity https://t.co/CL6Mr3cs7J
Links:
Dr. John Cush RheumNow ( View Tweet)